Merits of Darbepoetin utilization in the elderly CKD patients

Cresp®, the world's first biosimilar darbepoetin alfa, offers
improved, convenient, and affordable treatment for anemia¹

Maintaining Hb Targets in Elderly CKD Patients

*Subjects who received at least one dose of darbepoetin.

Empowering Elderly CKD Patients:The Efficacy of Darbepoetin Alfa

Mean Hb levels for subjects ≥65 years and ≥75 years or older remained within the target range between 10 and 12 g/dL³

A secondary analysis of a 29-week multicenter, open-label, single-arm study with an initial 2-week screening/baseline period, followed by a 20-week once-monthly darbepoetin alfa dose titration period and an 8-week evaluation period.

Is Monthly Administrationof Darbepoetin Alfa Safe for the Elderly?

The safety profile observed in participants aged 65 years and older, as well as those aged 75 years and older, was similar to the safety profile observed in participants aged under 65 years.³

*The numbers reported for all adverse events are inclusive of all the other numbers listed.

Abbreviations: ▼

CKD: Chronic kidney disease; Hb: Hemoglobin; SD: Standard deviation.

References:▼

1. Cresp. Available at: https://www.cresp.in/development.html. Accessed on: 08 January 2024. 2. Alkatheri A, Albekairy A, Al-Rajhi Y, et al. Comparison of the effectiveness of equal doses of short and long-acting erythrocyte stimulating agents for managing anemia in chronic kidney disease adult patients. Int J Med Res Health Sci. 2016;5(12):335–342. 3. Agarwal A, Silver MR, Walczyk M, et al. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc. 2007;8(2):83–90.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-A24-0191

Cresp

Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Merits of Darbepoetin utilization in the elderly CKD patients

Related Articles

Login to continue